Abstract:Objectives To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids for the treatment of macular oedema (ME) secondary to central retinal vein occlusion (CRVO). Design Systematic review and network meta-analysis. Participants Patients from previously reported randomised controlled trials (RCTs) comparing anti-VEGF and corticosteroids for the treatment of ME secondary to CRVO. Methods Literature searches were conducted using PubMed, Medline, Embase, Cochrane Library and clinicaltrials.gov until March 2017. Therapeutic effects were estimated using the proportions of patients gaining/losing ≥15 letters, best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Treatment safety was estimated using the proportions of adverse events, namely increased intraocular pressure (IOP), cataracts, vitreous haemorrhage (VH) and retinal tear. The software ADDIS (V.1.16.8) was used for analysis. Treatment effect and safety of different drugs could be ranked based on simulation. Results Eleven RCTs comprising 2060 patients were identified. Regarding patients gaining ≥15 letters, aflibercept and ranibizumab were significantly more effective than sham/placebo at 6 months. Regarding patients losing ≥15 letters at 6 months, ranibizumab showed significant improvement compared with dexamethasone. Aflibercept, bevacizumab or ranibizumab showed greater improvements in BCVA than sham/placebo at 6 months. Intravitreal ranibizumab injection demonstrated greater CRT reduction than both sham and dexamethasone did. Dexamethasone had a higher risk of increased IOP than aflibercept and ranibizumab. Ranibizumab demonstrated a greater risk of cataracts than dexamethasone. Aflibercept and ranibizumab demonstrated low incidence of VH and retinal tear, respectively. Aflibercept had a slight advantage over ranibizumab as assessed by benefit–risk analysis. Conclusions Anti-VEGF agents have advantages in the treatment of ME secondary to CRVO. Aflibercept and ranibizumab showed marked BCVA improvement and CRT reduction. Aflibercept may have a slight advantage over ranibizumab. The results of this study can serve as a reference for clinicians to provide patient-tailored treatment. PROSPERO registration number CRD42017064076.

Research Progress on the Pathogenesis of Macular Edema Secondary to Retinal Vein Occlusion and the Effect of Macular Edema on Visual Function

The main effective factors for the visual outcome of macular edema secondary to central retinal vein occlusion

Roles of hypoxia and inflammation in the pathogenesis of macular edema secondary to retinal vein occlusion

The role of retinal glial cells and related factors in macular edema

Recurrence of macular edema in patients with branch retinal vein occlusion: a proteomic study

Macular edema after retinal vein occlusions. Macular morphometry and chorioretinal hemodynamics

Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion

Analyze of Factors and Prognosis of Eyes Lost to Follow-Up in Retinal Vein Occlusive Disease Patients Receiving Anti-Vascular Endothelial Growth Factor Therapy

Anti-VEGF Reduces Inflammatory Features in Macular Edema Secondary to Retinal Vein Occlusion.

Research status and progress of macular edema formation mechanism

Intravitreal Anti-Vegf Agents, Oral Glucocorticoids, And Laser Photocoagulation Combination Therapy For Macular Edema Secondary To Retinal Vein Occlusion: Preliminary Report

Comparative Efficacy of Intravitreal Pharmacotherapy for Macular Edema Secondary to Retinal Vein Occlusion

Comparative Efficacy of Intravitreal Pharmacotherapy for Macular Edema Secondary to Retinal Vein Occlusion: A Protocol for the Systematic Review and Network Meta-Analysis.

Effect of Anti-Vegf Treatment on Nonperfusion Areas in Ischemic Retinopathy.

Anti-VEGF Maintains The Function of Retinal Pigment Epithelium In Patients With Retinal Vein Occlusion

Comparison of the Efficacy and Safety of Drug Therapies for Macular Edema Secondary to Central Retinal Vein Occlusion.

Comparison of the efficiency of anti-VEGF drugs intravitreal injections treatment with or without retinal laser photocoagulation for macular edema secondary to retinal vein occlusion: A systematic review and meta-analysis

Cytokines and Pathogenesis of Central Retinal Vein Occlusion

A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics

Comparative Efficacy of Intravitreal Pharmacotherapy for Macular Edema Secondary to Retinal Vein Occlusion: a Systematic Review and Network Meta-Analysis

Chinese Herbal Medicine Combined with Intravitreal Antivascular Growth Factor Agents in Treatment of Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review and Meta-Analysis